DEM
FBLG icon

Disciplined Equity Management’s FibroBiologics FBLG Stock Holding History

Disciplined Equity Management’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50
Closed -$418 – 62
2025
Q4 		$418 Buy
+50
New +$352 ﹤0.01% 63

Other funds holding FBLG

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FEG
Fund Evaluation Group Cincinnati, Ohio $3.7B AUM 16.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM

Disciplined Equity Management's FBLG Position: Q1 2026 in Review

Disciplined Equity Management sold out of FibroBiologics (FBLG) in Q1 2026, closing a stake of 50 shares — an estimated $418 sold.

Disciplined Equity Management first reported a position in FBLG in Q4 2025 and held it in 1 quarter. The position peaked at $418 in Q4 2025. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

  • Disciplined Equity Management reported no remaining FibroBiologics position as of Q1 2026 after selling out during the quarter.
  • Disciplined Equity Management sold 50 FibroBiologics shares in Q1 2026, an estimated $418.
  • Disciplined Equity Management first reported a position in FibroBiologics in Q4 2025 and held it in 1 quarter.
  • Disciplined Equity Management's FibroBiologics position peaked at $418 in Q4 2025.
  • 17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on Disciplined Equity Management's 13F filing for Q1 2026, filed 28 Apr 2026.